CAS 55314-16-4

3-Dimethylamino-1-(3-pyridyl)-2-propen-1-one

Description:

1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one can be used in the synthesis of imatinib and nilotinib (AMN107), a compound currently in multiple Phase II/III clinical trials for chronic granulocytic leukaemia. Imatinib, on the other hand, is a cancer growth blocker known as a tyrosine kinase inhibitor (TKI), which is used to treat a wide range of leukaemias, myelodysplastic/myeloproliferative disorders, systemic mastocytosis, eosinophilia syndromes, raised dermal fibrosarcoma and gastrointestinal mesenchymal tumours.

Formula: C₁₀H₁₂N₂O

InChI: InChI=1/C10H12N2O/c1-12(2)8-5-10(13)9-3-6-11-7-4-9/h3-8H,1-2H3/b8-5+

InChI key: InChIKey=MZLRFUCMBQWLNV-UHFFFAOYSA-N

SMILES: C(C=CN(C)C)(=O)C=1C=CC=NC1

Synonyms:

• (2E)-3-(dimethylamino)-1-pyridin-3-ylprop-2-en-1-one
• (2E)-3-(dimethylamino)-1-pyridin-4-ylprop-2-en-1-one
• 2-Propen-1-one, 3-(dimethylamino)-1-(3-pyridinyl)-
• 3-(Dimethylamino)-1-(3-pyridinyl)-2-propen-1-one
• 3-(Dimethylamino)-1-(Pyridin-3-Yl)Prop-2-En-1-One
• 3-Dimethylamino-1-(3-pyridyl)-2-propen-1-one
• 3-Dimethylamino-1-(pyridin-3-yl)propenone
• 1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one
• 1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one ,97%
• 1-(3-PYRIDYL)-3-(DIMETHYLAMINO)-2-PROPEN-1-ONE 95%
• 3-(Dimethylamino)-1-pyridin-3-ylprop-2-en-1-one

3-(Dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one

CAS: 55314-16-4

3-(Dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one

Formula: C₁₀H₁₂N₂O

Purity: 96%

Color and Shape: Solid

Molecular weight: 176.21508

Ref: 54-OR14051

1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one

CAS: 55314-16-4

Formula: C₁₀H₁₂N₂O

Purity: 96%

Color and Shape: Solid

Molecular weight: 176.2151

Ref: IN-DA003CXR

3-Dimethylamino-1-(3-pyridyl)-2-propen-1-one

Controlled Product

CAS: 55314-16-4

Impurity EP Impurity A
Applications 3-Dimethylamino-1-(3-pyridyl)-2-propen-1-one (Imatinib EP Impurity A) is an Imatinib intermediate. It is a COVID19-related research product.
References Bennett, G., et al.: J. Med. Chem., 21, 623 (1978), Buchdunger, E., et al.: J. Pharmacol. Exp. Ther., 295, 139 (2000), Krystal, G., et al.: Clin. Cancer Res., 6, 3319 (2000), van Oosterom, A., et al.: Lancet, 358, 1421 (2001),

Formula: C₁₀H₁₂N₂O

Color and Shape: Neat

Molecular weight: 176.22

Ref: TR-D462145

1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one

CAS: 55314-16-4

1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one

Formula: C₁₀H₁₂N₂O

Purity: 96%

Molecular weight: 176.22

Ref: IN-DG41794

Imatinib EP Impurity A (Mixture of Z/E-Isomer)

CAS: 55314-16-4

Formula: C₁₀H₁₂N₂O

Molecular weight: 176.22

Ref: 4Z-I-0975

Imatinib EP Impurity A

CAS: 55314-16-4

Formula: C₁₀H₁₂N₂O

Molecular weight: 176.22

Ref: ST-EA-CP-I5001

1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one

CAS: 55314-16-4

Formula: C₁₀H₁₂N₂O

Purity: 98%

Color and Shape: Solid

Molecular weight: 176.219

Ref: 10-F047914

3-Dimethylamino-1-(3-pyridyl)-2-propen-1-one

CAS: 55314-16-4

3-Dimethylamino-1-(3-pyridyl)-2-propen-1-one is a synthetic anticancer compound. It is an amide derivative of 3-dimethylamino-1-(3-pyridyl)-2-propenal, which is synthesized by reacting 3,5,6,7 tetrahydrobenzo[b]thiophene with 3-(dimethylamino)acrylic acid chloride. The synthesis of 3DAP was reported in 1974 by Novartis Pharmaceuticals Corporation and it has been used as a lead compound for the development of other anticancer agents. This drug can inhibit the growth of myelogenous leukemia cells and has been shown to be effective against cancer cells that are resistant to imatinib.

Formula: C₁₀H₁₂N₂O

Purity: Min. 95%

Color and Shape: Off-White To Yellow Solid

Molecular weight: 176.22 g/mol

Ref: 3D-FD22332